Search research articles
Contact Us
Filters
Showing results (31-40 of 71) with videos related to
Page
of 8
Sort By:
JAMA
|
November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial
Theodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
European Journal of Heart Failure
|
February 17, 2021
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial
Jawad H Butt, Jose C Nicolau, Subodh Verma, et al.
JACC. Heart Failure
|
April 28, 2022
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial
Su Ern Yeoh, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure
|
July 28, 2022
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF
Jawad H Butt, Pooja Dewan, Ersilia M DeFilippis, et al.
Journal of the American College of Cardiology
|
March 27, 2024
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
Toru Kondo, Ulrik M Mogensen, Atefeh Talebi, et al.
Circulation
|
November 19, 2019
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
Felipe A Martinez, Matteo Serenelli, Jose C Nicolau, et al.
JACC. Asia
|
November 7, 2022
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Kieran F Docherty, Inder S Anand, Chern-En Chiang, et al.
The Lancet. Diabetes & Endocrinology
|
November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
Silvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
Circulation
|
April 11, 2023
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
Su Ern Yeoh, Kieran F Docherty, Ross T Campbell, et al.
Circulation. Heart Failure
|
November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
Jawad H Butt, Carly Adamson, Kieran F Docherty, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 71) with videos related to
Sort By:
Page
of 8
JAMA
|
November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial
Theodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
European Journal of Heart Failure
|
February 17, 2021
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial
Jawad H Butt, Jose C Nicolau, Subodh Verma, et al.
JACC. Heart Failure
|
April 28, 2022
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial
Su Ern Yeoh, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure
|
July 28, 2022
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF
Jawad H Butt, Pooja Dewan, Ersilia M DeFilippis, et al.
Journal of the American College of Cardiology
|
March 27, 2024
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
Toru Kondo, Ulrik M Mogensen, Atefeh Talebi, et al.
Circulation
|
November 19, 2019
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
Felipe A Martinez, Matteo Serenelli, Jose C Nicolau, et al.
JACC. Asia
|
November 7, 2022
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Kieran F Docherty, Inder S Anand, Chern-En Chiang, et al.
The Lancet. Diabetes & Endocrinology
|
November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
Silvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
Circulation
|
April 11, 2023
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
Su Ern Yeoh, Kieran F Docherty, Ross T Campbell, et al.
Circulation. Heart Failure
|
November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
Jawad H Butt, Carly Adamson, Kieran F Docherty, et al.
Page
of 8